Data support progressing obe-cel as a treatment for srSLE and 50M has been selected as the recommended Phase 2 dose. Autolus has aligned with U.S. Food and Drug Administration (FDA) on a Phase 2 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback